Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
275 USD | -0.51% | -0.05% | +25.06% |
Jun. 03 | Liquidia's Yutrepia Launch Cleared as Court Denies Injunction | MT |
May. 16 | United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing | MT |
Evolution of the average Target Price on United Therapeutics Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering United Therapeutics Corporation
UBS | |
Oppenheimer | |
Goldman Sachs | |
Leerink Partners | |
Wedbush | |
Morgan Stanley | |
Ladenburg Thalmann | |
Argus | |
Credit Suisse | |
HC Wainwright | |
JPMorgan Chase | |
Jefferies & Co. | |
BTIG | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- UTHR Stock
- Consensus United Therapeutics Corporation